

A systematic approach to improving the reliability and scale of evidence from health care data

Martijn J. Schuemie ^{1,2,*}, Patrick B. Ryan ^{1,2,3}, George Hripcsak ^{1,3,4},
David Madigan ^{1,5}, Marc A. Suchard ^{1,6,7,8}

1. Observational Health Data Sciences and Informatics (OHDSI), New York, NY 10032
2. Epidemiology Analytics, Janssen Research and Development, Titusville, NJ 08560
3. Department of Biomedical Informatics, Columbia University Medical Center, New York, NY 10032
4. Medical Informatics Services, New York-Presbyterian Hospital, New York, NY 10032
5. Department of Statistics, Columbia University, New York, NY 10027
6. Department of Biomathematics, University of California, Los Angeles, CA 90095
7. Department of Biostatistics, University of California, Los Angeles, CA 90095
8. Department of Human Genetics, University of California, Los Angeles, CA 90095

*To whom correspondence should be addressed. E-mail: schuemie@ohdsi.org

Abstract

Concerns over reproducibility in science extend to research using existing healthcare data; many observational studies investigating the same topic produce conflicting results, even when using the same data. To address this problem, we propose a paradigm shift. The current paradigm centers on generating one estimate at a time using a unique study design with unknown reliability and publishing (or not) one estimate at a time. The new paradigm advocates for high-throughput observational studies using consistent and standardized methods, allowing evaluation, calibration, and unbiased dissemination to generate a more reliable and complete evidence base. We demonstrate this new paradigm by comparing all depression treatments for a set of outcomes, producing 17,718 hazard ratios, each using methodology on par with state-of-the-art studies. We furthermore include control hypotheses to evaluate and calibrate our evidence generation process. Results show good transitivity and consistency between databases, and agree with four out of the five findings from clinical trials. The distribution of effect size estimates reported in literature reveals an absence of small or null effects, with a sharp cutoff at $p = 0.05$. No such phenomena were observed in our results, suggesting more complete and more reliable evidence.

Introduction

Great concern exists over reproducibility in science, with many scientists even using the term ‘reproducibility crisis’ (1). Low sample size, small effect sizes, data dredging (including P-hacking), conflicts of interest, large numbers of scientists working competitively in silos without combining their efforts, and so on, may conspire to dramatically increase the probability that a published finding is incorrect (2). Although many solutions have been proposed, including pre-registering studies, open science, team research, and better reporting, adoption of these solutions is still lacking (3, 4). Here we focus on reproducibility in observational research using existing health care data, where we believe a complementary solution is viable that would vastly improve reproducibility, while at the same time generate large amounts of reliable scientific evidence.

Existing health care data, such as claims and electronic health records, hold the promise of providing new insights to improve patient care. These data capture details of real-world experiences of patients and their encounters with the health care system, allowing the study of many types of therapies and revealing benefits received and harm done. Certainly, there exist limits to the range of questions that these data can answer as they are based on interactions with the healthcare system and depend on accurate recording of events. There is also an information asymmetry as ‘harms’ tend to come to medical attention and are easily reflected in these data while ‘benefits’ are often neither easily reflected in these data nor do they tend to drive patients to clinical encounters. Observational studies are more susceptible to bias, placing them lower in the hierarchy of clinical evidence than randomized clinical trials. Nonetheless, these data could yield a wealth of insights that go well beyond what can be explored through other sources of evidence.

Current observational research relies on one-off studies answering one question at a time with unique methodology and therefore unknown reliability, and disseminating these results (or not) one estimate at a time. Here we propose to unlock the potential of existing health care data by defining a high-throughput approach to observational research; we systematically compare all treatments for a given indication for a large set of outcomes captured in data from the

Observational Health Data Science and Informatics (OHDSI) (5) research network. We adjust for measured confounders using propensity score stratification, a state-of-the-art confounder-adjustment strategy, but instead of the current practice of hand-picking covariates for the propensity model, we employ a completely data-driven approach to variable selection. In addition, uncertainty due to residual observational study bias, for example due to unmeasured confounders, is quantified by using control hypotheses (research questions with known answers). We employ both real negative control hypotheses (where the true hazard ratio is known to be 1) as well as synthetic positive control hypotheses (where the true hazard ratio is of known magnitude greater than 1), created by modifying negative controls. We subsequently express the observed uncertainty due to residual bias in calibrated confidence intervals (CIs) (6). We disseminate all results, thereby not only providing evidence at large scale, but also preventing publication bias. We demonstrate this new paradigm by comparing all treatments for depression for a large set of health outcomes using four large insurance claims databases, as depicted in Figure 1.




Figure 1. High-throughput observational study design with empirical calibration, applied to the comparison of depression treatments. We apply this design to four large insurance claims databases.

We evaluate our results in terms of transitivity and between-database consistency, and agreement with effects known from clinical trials. We also show that our distribution of estimates is markedly different from the distribution observed in literature, suggesting more complete and more reliable evidence.

Results

Example single research hypothesis

We demonstrate our high-throughput process by first showing the analysis for a single research question: the comparison of duloxetine to sertraline for the risk of stroke, using the Truven MarketScan Commercial Claims and Encounters (CCAE) database. We compare our approach to a previously published study by Lee et al.(7). Whereas that study compares new users of the entire drug classes to which these drugs belong, our analysis investigates new users of the two specific drugs. Both Lee et al. and our analysis require 12 months of continuous observation prior to treatment initiation, exclude people exposed to both drugs and people with prior strokes, and use stratification on the propensity score to address confounding. Follow-up is defined as starting on the day of treatment initiation and stopping on the day of the outcome, discontinuation of treatment (allowing a 30 day-gap between treatments), or disenrollment. Lee et al. hand-picked 74 covariates such as age, sex, and various selected drugs and diagnoses to create a propensity model. In contrast, we used a data-driven approach to generate a propensity model based on 59,038 covariates. Figure 2A shows our propensity score distribution across new users.

For many subjects, treatment assignment is highly dependent upon their baseline characteristics, indicating that the groups are fundamentally different and that without adjustment there is a high likelihood of confounding. On the other hand, Figure 2A also reveals substantial overlap, implying that propensity score adjustment should be able to make the groups equivalent, at least with regard to measured covariates. Indeed, Figure 2B shows that many covariates are imbalanced prior to adjustment, but after stratification all covariates have a standardized difference of mean smaller than 0.1, generally assumed to indicate adequate

balance. This includes any covariates that experts might consider relevant such as comorbidities and current or prior medication use.




Figure 2. Cohort comparability and balance for duloxetine versus sertraline new users from the CCAE database. (A) Propensity score distributions for each cohort. (B) Absolute values of the standardized difference of the mean before and after stratification for the 59,038 covariates established at baseline.

For stroke risk, our analysis produces a propensity score-adjusted hazard ratio of 1.13 (95% CI: 0.81-1.61). This result stands in agreement with Lee et al.(7) who report an adjusted hazard ratio of 1.01 (95% CI: 0.90-1.12). Both studies also include sensitivity analyses that consider an alternative time-at-risk definition and show little variation in the estimate. We argue that the method used in both studies is of comparable rigor, and that our analysis meets the criteria for peer review, demonstrated by the publication of our studies using similar designs (8-10).

Figure 3 shows the estimates produced by applying the same analysis to a set of control outcomes (outcomes where the hazard ratio is known), while still comparing duloxetine to sertraline. This figure reveals the coverage of the uncalibrated 95% CI to be smaller than 95%. Calibrating the CIs using these observed operating characteristics restores near-nominal coverage.




Figure 3. Evaluation of effect estimation between duloxetine and sertraline new users after stratification on the propensity scores before (top) and after (bottom) calibration. Each dot represents the hazard ratio and corresponding standard error for one of the negative (true hazard ratio = 1) or positive control (true hazard ratio > 1) outcomes.

Using the same calibration process, our hazard ratio for stroke becomes 1.11 (95% CI: 0.77-1.62), compared to the uncalibrated estimate of 1.13 (95% CI: 0.81-1.61). Although these estimates are similar, the empirical evaluation and calibration provide confidence that systematic error in our calibrated estimate remains small.

Results of all comparisons

With four databases, the potential number of effect size estimates is ($4 * 5,984 =$) 23,936. We generate no risk estimate if at least one of the two treatment groups in a comparison contains less than 2,500 persons, so the final count is 17,718 estimates. The full set of results are available in the Supplementary Materials and can be explored online at <http://data.ohdsi.org/SystematicEvidence>. The results of our evaluation and calibration using control outcomes, verified by cross-validation can be found in the Supplementary Materials. The distribution of calibrated effect size estimates is also shown in figure 5C.

Effect transitivity

If drug A has a statistically significant higher risk than drug B for a particular outcome, and drug B has a statistically significant higher risk than C for that same outcome, we expect A to have a statistically significant higher risk than C. In total, we identified 755 such A-B-C combinations, of which for 722 triplets (96%) the transitivity property held.

Between-database consistency

Our previous work has suggested remarkably high heterogeneity when uncalibrated but identical observational study designs are implemented in different databases (11). In the present context, ideally, calibrated effects estimated across the four observational databases would be relatively consistent. For the 2,570 target-comparator-outcome triplets having sufficient data in all four databases, we compute the I^2 heterogeneity metric (12). An I^2 of zero means no between-database heterogeneity is observed. Across databases, 83% of calibrated estimates have an I^2 below 0.25; see Figure 4 for a complete histogram. In contrast, and in line with our previous work, only 58% of the estimates have an I^2 below 0.25 when no calibration is applied.




Figure 4. I^2 distribution for all 2,570 target-comparator-outcome triplets for which there was enough data in all four databases. Blue shows the distribution before calibration, red shows the distribution after calibration.

Consistency with established knowledge

An additional test of validity compares our results with the current literature. Gartlehner et al. (13) systematically review comparative effects of antidepressant treatments based on randomized clinical trials (RCTs) and observational studies. Five findings emerge from the RCTs: 1) sertraline has higher risk of diarrhea than comparators; 2) venlafaxine has higher risk of nausea than selective serotonin reuptake inhibitors (SSRIs); 3) there is no difference in nausea between duloxetine and paroxetine or fluoxetine; 4) paroxetine has higher rate of sexual dysfunction than fluoxetine and sertraline; and 5) bupropion has lower incidence of sexual

dysfunction than fluoxetine, paroxetine, and sertraline. Our result set correctly identified findings 1 through 4, as discussed in the Supplementary Materials—implying substantial but not perfect agreement with the literature. Supplementary Figure S3 also compares our results for finding 1 to estimates from RCTS reported in a systematic review on the topic (14), showing agreement as well as greater precision in our estimates due to the much larger sample size.

Finding 5 follows from five RCTs that demonstrated a significant lower rate of sexual adverse events in patients exposed to bupropion relative to SSRIs. Clinical guidelines suggest bupropion as an alternative treatment if a patient experiences sexual side effects with an SSRI medication (15) and other supporting trials recommend bupropion for patients for whom sexual dysfunction is a concern (16). From our result set, three databases return increased risks associated with bupropion relative to sertraline and fluoxetine. For example, in CCAE, the calibrated hazard ratio for decreased libido between bupropion and sertraline new users is 1.43 (1.09 – 1.89) and 1.42 (1.10 – 1.84) relative to fluoxetine new users. Channeling bias due to unmeasured baseline characteristics, such as sexual behavior, may explain this discordant finding.

Comparing the distribution of estimates with the literature

To compare our approach to the current scientific process, we show the distribution of effect size estimates from observational studies reported in the literature (Figure 5A), the subset of estimates for depression treatments (Figure 5B), and compare it against estimates produced in the high-throughput study described in this paper (Figure 5C). At least three observations emerge from the current corpus of published observational studies. First, *the vast majority of effect estimates in literature abstracts (>80%) have a confidence interval (CI) that excludes one* (i.e., statistically significant effects at $p < 0.05$). One explanation posits that researchers select hypotheses to test that have high *a priori* probabilities of being true. Another explanation is that observational studies are vulnerable to bias, for example due to confounding, selection bias, and measurement error, that can easily lead to statistically significant but erroneous results (17). Yet another explanation is that there is a tendency to only report results when the CI excludes one, resulting in publication bias. This ties into our second observation: *In evidence*

reported in the literature there is a sharp boundary between the regions where the CI does and does not include one, suggesting that publication bias is pervasive. Third, when focusing on one specific area of interest (Figure 5B), in this case depression treatments, *the literature is sparse* compared to the more exhaustive approach taken in our study. Few of the questions that could have been asked are truly answered in literature, perhaps because the current process is too inefficient, slow, or because of the demonstrated publication bias.




Figure 5. Effect size estimates from the literature (A, B) and the study described in this paper (C). Each dot represents a single estimate, such as relative risk, odds ratio, or hazard ratio, and corresponding standard error (linearly related to the width of the asymptotic confidence interval (CI)). Estimates below the red dashed line have a CI that excludes one, suggesting a non-null effect. Plot A shows estimates extracted from the abstracts of all observational research papers in MEDLINE, plot B shows only the subset of those that are related to depression treatments. Plot C shows estimated and calibrated hazard ratios for comparisons between depression treatments for various health outcomes of interest, generated from observational data in a single study using a systematic process. An online interactive visualization enables readers to explore these results in detail, including individual study artifacts for the estimates we generated (<http://data.ohdsi.org/SystematicEvidence>)

Discussion

The distribution of estimates extracted from the literature (Figures 5A and 5B) exposes several concerns: Answers to many relevant questions are missing, either because they have not yet been investigated, or because publication bias hides effect sizes close to or equal to one. In addition, evidence that is present is unreliable for two reasons. One reason is the evident publication bias, making a high false-positive rate likely (2). In aggregate, published observational research is akin to data fishing at a massive proportion; by reporting primarily ‘statistically significant’ results and hiding others, spurious results due to random error appear legitimate because no adjustment is possible for the hidden multiple testing. The second reason

is the proliferation of observational study bias (17). Indeed, observational research literature stands replete with multiple studies reporting statistically significant results in conflicting directions, even when employing the same data (18-27).

Applying a high-throughput observational study design can address these problems, as we have demonstrated in our example study comparing the effects of depression treatments: First, the evidence from such a study can be produced and disseminated as a single unit, and thereby prevent publication bias from reducing the validity of our results. Second, the inclusion of control hypotheses allows for evaluation of our study, measuring its operating characteristics such as coverage of the CI. We even use these measures to calibrate our results to restore nominal characteristics, as confirmed in our experimental results. Consequently, our estimates have a markedly different distribution compared with those found in the current literature, as demonstrated by comparing Figures 5A, 5B and 5C.

Does quantity come at the cost of quality?

A potential criticism to our approach is that addressing many research questions at once is at odds with thoughtful study design for any single question, and therefore likely leads to lower quality research. However, each of our analyses is of high quality, sufficient to pass peer review as demonstrated by comparing our duloxetine-sertraline-stroke example to a published study and our prior publications using similar designs. Similarly, our evaluation using control hypotheses provides further confidence in the quality of our designs and goes above and beyond the recent tentative calls to include negative controls in observational studies (28, 29).

In fact, we believe unfettered freedom to customize a study for any research question is one of the main causes of the lack of reproducibility of observational study results, leading us to the situation portrayed in Figure 5A. Our challenge to the scientific community is to point out changes to our study design that researchers believe to be necessary when answering a particular question. Such changes should be evaluated objectively on their merit, for example using control hypotheses, and if proven to indeed improve quality, can be incorporated in a systematic way in the overall study design. Thus, science can move forward in a meaningful way, out of the current crisis.

Limitations

We require our negative controls to be truly negative, but we rarely have definitive evidence of the absence of a causal relationship. We must assume that a lack of evidence of an effect for well-studied treatments and outcomes implies evidence of a lack of effect. In reality, some of our negative controls could prove to be positive at a future point in time.

In our evaluation and calibration procedure we require that the controls and the hypotheses of interest are exchangeable in certain aspects. We address this by choosing controls with the same target and comparator definitions, only differing in the outcome. However, negative controls could exhibit different bias than the outcomes of interest. Note that we do not assume the biases for these controls exactly equal the biases for the outcomes of interest, rather we assume only that biases draw from the same distribution. Unfortunately, we do not know for certain that this broad assumption holds. Furthermore, our positive controls fail to reflect bias due to unmeasured confounding other than that present for the negative controls on which they were based. However, we argue that detection of bias that may not fully represent all bias is better than ignoring bias completely.

A further limitation of observational research in general is that evidence can be generated only for those treatments and outcomes that are captured during interactions with the health care system and are reflected in the data. Some outcomes cannot be studied using these data. For example, we could not study reduction in depression symptoms as a possible outcome of treatment. Unmeasured confounding factors, as may have biased the estimate of the effect of bupropion on sexual dysfunction, remain a potential threat to the reliability of observational studies.

How to use our results

Despite the limitations of observational data, they represent a critical component in improving the health care evidence base. Even though depression treatments have been extensively studied with hundreds of clinical trials, there is still much we do not know about the comparative effectiveness (including safety and tolerability) of alternative treatments. Evidence from our observational study can provide a reference to compare what we have learned in

trials with what is observed in the real world. The evidence can also be a primary source when trials are unavailable, underpowered, or non-generalizable to the target population of interest.

We believe that our results should be used similarly to how one would use results currently scattered across observational research papers in the literature, which is typically a hypothesis-driven process. We purposely do **not** correct for multiple hypotheses in our results because that can only be done once a hypothesis or set of hypotheses is chosen. As when using results from literature, it is important to consider false positives when faced with multiple testing, and our results readily allow for adjustment for multiple testing, because we have disseminated all results. Note that such adjustments are not possible when using evidence scattered in literature, because many studies that should have been considered were never published due to publication bias. If readers dredge our results set looking for the most statistically significant ones, appropriate interpretation will require a multiplicity correction (e.g., Bonferroni or false discovery rate analysis). We believe that the value of our results, however, lies not in finding a few very significant ones, but in having available results that are poised to answer specific questions with as little bias as currently possible in observational research.

Significance

To illustrate an example from our results, consider the outcome of suicidality. All antidepressants have FDA product labels that contain a black boxed warning for suicidal thinking and behavior. However, despite the considerable attention and public health importance of the outcome, “evidence from existing studies is insufficient to draw conclusions about the comparative risk of suicidality” (13). Our results readily provide evidence on this question, and to demonstrate this we consider SSRIs, the most prevalent class of antidepressants, and compare them to amitriptyline and bupropion, two other highly prevalent drugs that are not SSRIs. Our results in Figure 6 suggest that SSRIs (sertraline, fluoxetine, citalopram, escitalopram) may have an increased risk of suicidality relative to amitriptyline and bupropion. Evidence for other hypotheses similarly left unanswered by clinical trials could serve a valuable role to inform medical decision-making when weighing the collective benefits and harms of alternative treatments.




Figure 6. Subset of hazard ratio (HR) estimates and calibrated 95% confidence intervals (CI) generated in our study, for the outcome of suicide or suicidal ideation.

Improving our study

While our choice of methods to address confounding (data-driven propensity score matching) and residual bias (confidence interval calibration) can be considered the current state-of-the-art, future studies could replace these with improved methods. In fact, we sincerely hope that observational researchers will move their focus from performing one-off studies to refining the high-throughput approach as described in this paper. Rather than each researcher working in isolation, we hope the scientific community will come together to build the process that generates evidence. To facilitate this, we have made all software necessary to execute this study available as open source.

Conclusion

We propose a paradigm shift in how researchers generate and disseminate evidence from observational data. The current paradigm centers on generating one estimate at a time using a unique study design with unknown operating characteristics and publishing estimates one at a

time through a dissemination process with clear limitations. The new paradigm advocates for larger scale studies that produce concurrent results for multiple hypotheses using consistent and standardized methods, allowing evaluation, calibration, and unbiased dissemination to generate a more reliable and complete evidence base than was previously possible. The results are poised for answering specific questions, able to be adjusted for multiple hypotheses as appropriate to the question at hand. Clinicians, regulators, and other medical decision makers can improve the care for patients by making well-informed decisions based on this evidence, and every treatment a patient receives becomes the basis for further evidence.

Materials and Methods

Comparison of depression treatments

As an example of our proposed high-throughput observational research we focus on the risk of specific outcomes across treatment choices for major depressive disorder. Depression is the leading cause of disability worldwide, affecting an estimated 350 million people globally (30), with multiple pharmacological and non-pharmacological treatments from which to choose. We identified 17 depression treatments to compare, and 22 outcomes of clinical interest (see Table 1). As a result, we have $17 * (17-1) * 22 = 5,984$ research questions.

Our study follows a typical comparative effectiveness design (31), comparing a target treatment (T) to a comparator treatment (C) for the risk of an outcome (O). We create definitions of all Ts, Cs, and Os listed in Table 1, based on clinical knowledge and our understanding of the databases (see Supplementary Materials), and pre-specify the rules by which these definitions should be adapted for any specific combination of T, C, and O. For example, T and C are restricted to the calendar time when both treatments were recorded in the database, and people with prior O are removed from both T and C. Because of the observational nature of the study, subjects in T may differ from subjects in C in ways that could bias effect estimation. We apply a commonly used confounding adjustment strategy – stratification by propensity scores - to make the two cohorts more comparable. We define time-at-risk to start on the day of treatment initiation and stop when treatment stops, allowing

for a 30-day gap in treatment continuation. We specify a sensitivity analysis where the time-at-risk is defined to stop at end of observation (end of enrollment or end of study period, whichever comes first). Hazard ratios are estimated using a Cox proportional model conditioned on the propensity score strata.

Treatments of interest	Outcomes of interest
Amitriptyline	Acute liver injury
Bupropion	Acute myocardial infarction
Citalopram	Alopecia
Desvenlafaxine	Constipation
Duloxetine	Decreased libido
Electroconvulsive therapy	Delirium
Escitalopram	Diarrhea
Fluoxetine	Fracture
Mirtazapine	Gastrointestinal hemorrhage
Paroxetine	Hyperprolactinemia
Psychotherapy	Hyponatremia
Sertraline	Hypotension
Trazodone	Hypothyroidism
Venlafaxine	Insomnia
Vilazodone	Nausea
	Open-angle glaucoma
	Seizure
	Stroke
	Suicide & suicidal ideation
	Tinnitus
	Vent. arr. & sudden cardiac death
	Vertigo

Table 1. Treatments and outcomes of interest

Propensity score stratification

Adjustment for baseline confounders is done by fitting a propensity model and creating propensity scores (PS) for every pair of exposures. The propensity score is the probability of a subject receiving one treatment instead of the other, conditional on baseline characteristics (32). We create a data-driven process that entertains a large set of predefined baseline covariates—often tens of thousands—consistently for all combinations of T, C and O, and use

the data to decide which combination of these characteristics are most predictive of the treatment assignment.

The following variables are included in all PS model:

- Demographics (age in 5-year increments, gender, race, ethnicity, year of index date, month of index date)
- Condition occurrence (one or more variables per diagnose code)
- Condition era (one or more variables per diagnose code)
- Condition group (one or more variables per MedDRA group or SNOMED groups)
- Drug exposure (one or more variables per drug code)
- Drug era (one or more variables per RxNorm ingredient)
- Drug group (one or more variables per ATC group)
- Procedure occurrence (one or more variables per procedure code)
- Observations (one or more variables per observation concept ID)
- Measurements (one or more variables per measurement concept ID, including variables for within / above / below normal range)
- Risk scores (including Charlson, DCSI, CHADS2, CHADS2VASc)

Variables with less than 100 non-zero values are discarded. For full details on the covariates used in our models please refer to FeatureExtraction package

<https://github.com/OHDSI/FeatureExtraction>

The PS models are fitted using L_1 regularized regression (33), using 10-fold cross-validation to select the regularization parameter. These PS are used to stratify the target and comparator cohorts in 10 strata, and the proportional hazards outcome models are conditioned on the strata (32).

Control hypotheses

We evaluate our process by applying it to research hypotheses where the truth is known with a high degree of certainty. Such a gold standard should include both negative and positive controls.

For comparative effectiveness studies, we define negative controls as TCO combinations where neither T nor C causes O and where therefore the true hazard ratio is equal to one. In practice, we identify negative controls by selecting exposures and outcomes that are well-studied, but for which no evidence in the literature or elsewhere suggests a relationship. For example, one negative control outcome is ‘ingrown nail’, because we firmly believe that no depression treatment causes ingrown nails. It is important to note that although there is no causal relationship, some antidepressants may be associated with ingrown nails, for example because the treatment is prescribed primarily for the elderly, where this condition is more prevalent. This allows us to test whether our confounding adjustment can correct for this confounding association, and produce estimates consistent with the null.

A candidate list of negative control outcomes was generated by identifying outcomes with no evidence of being causally related to any exposure of interest (34). This evidence was searched in literature through MeSH headings (35) and natural language processing (36), spontaneous reports of adverse events (37), and product labels in the US (38) and Europe (39). The candidate outcomes were then reverse sorted by prevalence in the observational databases and manually curated until a reasonably-sized set of negative controls was established. The final list of 52 negative control outcomes is provided in Table 2.

Positive controls in this case are outcomes believed to be caused by one exposure, but not the other. Unfortunately, real positive controls for observational research tend to be problematic for three reasons: First, when comparing the effect of two treatments there often is a paucity of positive controls relevant for that specific comparison. Second, even if positive controls are available, the magnitude of the effect size may not be known with great accuracy, and often depends on the population in which it is measured. Third, when treatments are widely known to cause a particular outcome, this will shape the behavior of physicians prescribing the treatment, for example by taking actions to mitigate the risk of unwanted outcomes, thereby rendering the positive controls useless as a means for evaluation (40). We therefore use synthetic positive controls (6), created by modifying a negative control through injection of additional, simulated occurrences of the outcome. To preserve (measured) confounding,

simulated outcome occurrences are sampled from the probability distribution derived from a predictive model fitted on the data. These models use the same covariates as the propensity models as independent variables, and the occurrence of the negative control outcomes as the dependent variables. Target true hazard ratios for the positive control synthesis are 1.5, 2, and 4, so using the 52 negative controls we are able to construct $52 * 3 = 156$ positive control outcomes for every comparison of two treatments. No negative control outcome model is fitted and no positive controls are created if there were less than 100 persons with the outcome across all exposures. No injection is performed if, for the exposure that is considered for injection, there were less than 25 persons with the outcome before injection.

Acariasis	Ingrowing nail
Amyloidosis	Iridocyclitis
Ankylosing spondylitis	Irritable bowel syndrome
Aseptic necrosis of bone	Lesion of cervix
Astigmatism	Lyme disease
Bell's palsy	Malignant neoplasm of endocrine gland
Benign epithelial neoplasm of skin	Mononeuropathy
Chalazion	Onychomycosis
Chondromalacia	Osteochondropathy
Crohn's disease	Paraplegia
Croup	Polyp of intestine
Diabetic oculopathy	Presbyopia
Endocarditis	Pulmonary tuberculosis
Endometrial hyperplasia	Rectal mass
Enthesopathy	Sarcoidosis
Epicondylitis	Scar
Epstein-Barr virus disease	Seborrheic keratosis
Fracture of upper limb	Septic shock
Gallstone	Sjogren's syndrome
Genital herpes simplex	Tietze's disease
Hemangioma	Tonsillitis
Hodgkin's disease	Toxic goiter
Human papilloma virus infection	Ulcerative colitis
Hypoglycemic coma	Viral conjunctivitis
Hypopituitarism	Viral hepatitis
Impetigo	Visceroptosis

Table 2. Negative control outcomes. Outcomes not believed to be caused by any of the exposures of interest.

With a gold standard in place, we evaluate whether our process produces results in line with the gold standard effect sizes. Importantly, we estimate CI coverage probability – the proportion of time that the CI contains the true value of interest. For example, we expect a 95% CI to cover the truth 95% of the time. We also apply a calibration procedure described elsewhere (6) that attempts to restore nominal coverage by adjusting the CIs, similarly to how one would calibrate a scale by using objects of known weight. In short, this procedure first estimates the distribution of systematic error using the observed estimates for negative and positive controls. We assume this distribution is Gaussian with a mean and log standard deviation linearly related to the true effect size. Using the estimated distribution, we then generate calibrated CIs considering both random and systematic error. Typically, but not necessarily, the calibrated CI is wider than the nominal CI, reflecting the problems unaccounted for in the standard procedure (such as unmeasured confounding, selection bias, and measurement error) but accounted for in the calibration.

Observational databases

The analyses have been performed across a network of observational healthcare databases. All databases have been transformed into the OMOP Common Data Model, version 5. The complete specification for OMOP Common Data Model, version 5 is available at:

<https://github.com/OHDSI/CommonDataModel>. The following databases have been included in this analysis:

- Truven MarketScan Commercial Claims and Encounters (CCAЕ)
- Truven MarketScan Medicare Supplemental Beneficiaries (MDCR)
- Truven MarketScan Multi-state Medicaid (MDCD)
- OptumInsight’s de-identified Clinformatics™ Datamart (Optum)

Truven MarketScan Commercial Claims and Encounters (CCAЕ)

CCAЕ is an administrative health claims database for active employees, early retirees, COBRA continues, and their dependents insured by employer-sponsored plans (individuals in plans or product lines with fee-for-service plans and fully capitated or partially capitated plans). As of 1 November 2016, CCAЕ contained 131 million patients with patient-level observations from

January 2000 through July 2016. Source codes used in CCAE include: conditions- ICD-9-CM; drugs: NDC, HCPCS, ICD-9-CM; procedures: CPT-4, HCPCS, ICD-9-CM; lab: LOINC.

The ETL specification for transforming CCAE into the OMOP CDM is available at:

https://github.com/OHDSI/ETL-CDMBuilder/tree/master/man/TRUVEN_CCAE_MDCR

Truven MarketScan Medicare Supplemental Beneficiaries (MDCR)

MDCR is an administrative health claims database for Medicare-eligible active and retired employees and their Medicare-eligible dependents from employer-sponsored supplemental plans (predominantly fee-for-service plans). Only plans where both the Medicare-paid amounts and the employer-paid amounts were available and evident on the claims were selected for this database. As of 1 November 2016, MDCR contained 9.6 million patients with patient-level observations from January 2000 through July 2016. Source codes used in MDCR include: conditions- ICD-9-CM; drugs: NDC, HCPCS, ICD-9-CM; procedures: CPT-4, HCPCS, ICD-9-CM; lab: LOINC.

The ETL specification for transforming MDCR into the OMOP CDM is available at:

https://github.com/OHDSI/ETL-CDMBuilder/tree/master/man/TRUVEN_CCAE_MDCR

Truven MarketScan Multi-state Medicaid (MDCD)

MDCD is an administrative health claims database for the pooled healthcare experience of Medicaid enrollees from multiple states. As of 1 November 2016, MDCD contained 21.6 million patients with patient-level observations from January 2006 through December 2014. Source codes used in MDCD include: conditions- ICD-9-CM; drugs: NDC, HCPCS, ICD-9-CM; procedures: CPT-4, HCPCS, ICD-9-CM; lab: LOINC.

The ETL specification for transforming MDCD into the OMOP CDM is available at:

https://github.com/OHDSI/ETL-CDMBuilder/tree/master/man/TRUVEN_MDCD

OptumInsight's de-identified Clinformatics™ Datamart (Optum)

OptumInsight's de-identified Clinformatics™ Datamart (Eden Prairie, MN) is an administrative health claims database for members of United Healthcare, who enrolled in commercial plans (including ASO, 36.31M), Medicaid (prior to July 2010, 1.25M) and Legacy Medicare Choice

numbers reported in the abstracts. For example, a hazard ratio of 1.5 was converted to a random number between 1.450000001 and 1.549999999.

A subset of articles related to depression treatment was identified using the PubMed query:

(depression OR antidepressant) AND ("serotonin reuptake inhibitors" OR "tricyclic antidepressant" OR Bupropion OR Mirtazapine OR Trazodone OR Desvenlafaxine OR duloxetine OR venlafaxine OR Citalopram OR Escitalopram OR Fluoxetine OR Paroxetine OR Sertraline OR vilazodone OR Amitriptyline OR Doxepin OR Nortriptyline or psychotherapy or "electroconvulsive therapy").

Acknowledgments

This work was supported in part through National Science Foundation grants IIS 1251151 and DMS 1264153, and National Institutes of Health grants R01 LM06910 and U01 HG008680. We would like to thank Christian Reich, Jon Duke, and Paul Stang for their constructive comment on this paper.

References

1. M. Baker, 1,500 scientists lift the lid on reproducibility. *Nature* **533**, 452-454 (2016).
2. J. P. Ioannidis, Why most published research findings are false. *PLoS medicine* **2**, e124 (2005).
3. M. R. Munafò *et al.*, A manifesto for reproducible science. *Nature Human Behaviour* **1**, 0021 (2017).
4. R. Dal-Ré *et al.*, Making Prospective Registration of Observational Research a Reality. *Science Translational Medicine* **6**, 224cm221-224cm221 (2014).
5. G. Hripcsak *et al.*, Characterizing treatment pathways at scale using the OHDSI network. *Proceedings of the National Academy of Sciences of the United States of America* **113**, 7329-7336 (2016).
6. M. J. Schuemie, G. Hripcsak, P. B. Ryan, D. Madigan, M. A. Suchard, Empirical confidence interval calibration for population-level effect estimation studies in observational healthcare data. *Proceedings of the National Academy of Science* **Accepted for publication**, (2017).
7. Y. C. Lee *et al.*, Comparison of the effects of serotonin-norepinephrine reuptake inhibitors versus selective serotonin reuptake inhibitors on cerebrovascular events. *The Journal of clinical psychiatry* **77**, e1-7 (2016).
8. J. D. Duke *et al.*, Risk of angioedema associated with levetiracetam compared with phenytoin: Findings of the observational health data sciences and informatics research network. *Epilepsia*, (2017).
9. D. Ramcharran, H. Qiu, M. J. Schuemie, P. B. Ryan, Atypical Antipsychotics and the Risk of Falls and Fractures Among Older Adults: An Emulation Analysis and an Evaluation of Additional Confounding Control Strategies. *Journal of clinical psychopharmacology* **37**, 162-168 (2017).
10. Y. Wang *et al.*, Incidence of diabetic ketoacidosis among patients with type 2 diabetes mellitus treated with SGLT2 inhibitors and other antihyperglycemic agents. *Diabetes research and clinical practice* **128**, 83-90 (2017).

11. D. Madigan *et al.*, Evaluating the impact of database heterogeneity on observational study results. *American journal of epidemiology* **178**, 645-651 (2013).
12. J. P. T. Higgins, S. G. Thompson, J. J. Deeks, D. G. Altman, Measuring inconsistency in meta-analyses. *BMJ (Clinical research ed.)* **327**, 557-560 (2003).
13. G. Gartlehner *et al.*, *Drug Class Review: Second Generation Antidepressants: Final Report Update 4.* (Oregon Health & Science University, Portland, Oregon., Portland OR, 2008).
14. A. Cipriani *et al.*, Sertraline versus other antidepressive agents for depression. *The Cochrane database of systematic reviews*, Cd006117 (2010).
15. A. J. Gelenberg *et al.*, Practice guideline for the treatment of patients with major depressive disorder third edition. *The American Journal of Psychiatry* **167**, 1 (2010).
16. P. W. Walker *et al.*, Improvement in fluoxetine-associated sexual dysfunction in patients switched to bupropion. *The Journal of clinical psychiatry* **54**, 459-465 (1993).
17. M. J. Schuemie, P. B. Ryan, W. DuMouchel, M. A. Suchard, D. Madigan, Interpreting observational studies: why empirical calibration is needed to correct p-values. *Statistics in medicine* **33**, 209-218 (2014).
18. C. R. Cardwell, C. C. Abnet, M. M. Cantwell, L. J. Murray, Exposure to oral bisphosphonates and risk of esophageal cancer. *Jama* **304**, 657-663 (2010).
19. F. de Vries, C. de Vries, C. Cooper, B. Leufkens, T. P. van Staa, Reanalysis of two studies with contrasting results on the association between statin use and fracture risk: the General Practice Research Database. *International journal of epidemiology* **35**, 1301-1308 (2006).
20. J. Green *et al.*, Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort. *BMJ (Clinical research ed.)* **341**, c4444 (2010).
21. F. Grodstein *et al.*, Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. *The New England journal of medicine* **335**, 453-461 (1996).
22. J. E. Manson *et al.*, Estrogen plus progestin and the risk of coronary heart disease. *The New England journal of medicine* **349**, 523-534 (2003).
23. L. C. Mayes, R. I. Horwitz, A. R. Feinstein, A collection of 56 topics with contradictory results in case-control research. *International journal of epidemiology* **17**, 680-685 (1988).
24. C. R. Meier, R. G. Schlienger, M. E. Kraenzlin, B. Schlegel, H. Jick, HMG-CoA reductase inhibitors and the risk of fractures. *Jama* **283**, 3205-3210 (2000).
25. T. P. van Staa, S. Wegman, F. de Vries, B. Leufkens, C. Cooper, Use of statins and risk of fractures. *Jama* **285**, 1850-1855 (2001).
26. C. Varas-Lorenzo, L. A. Garcia-Rodriguez, S. Perez-Gutthann, A. Duque-Oliart, Hormone replacement therapy and incidence of acute myocardial infarction. A population-based nested case-control study. *Circulation* **101**, 2572-2578 (2000).
27. P. W. Wilson, R. J. Garrison, W. P. Castelli, Postmenopausal estrogen use, cigarette smoking, and cardiovascular morbidity in women over 50. The Framingham Study. *The New England journal of medicine* **313**, 1038-1043 (1985).
28. B. F. Arnold, A. Ercumen, J. Benjamin-Chung, J. M. Colford, Jr., Brief Report: Negative Controls to Detect Selection Bias and Measurement Bias in Epidemiologic Studies. *Epidemiology (Cambridge, Mass.)* **27**, 637-641 (2016).
29. J. R. Desai *et al.*, Utilization of Positive and Negative Controls to Examine Comorbid Associations in Observational Database Studies. *Medical care* **55**, 244-251 (2017).
30. WHO, "WHO Fact Sheet: Depression," (2016).
31. M. A. Hernan, J. M. Robins, Using Big Data to Emulate a Target Trial When a Randomized Trial Is Not Available. *American journal of epidemiology* **183**, 758-764 (2016).

32. P. R. Rosenbaum, D. B. Rubin, The central role of the propensity score in observational studies for causal effects. *Biometrika* **70**, 41-55 (1983).
33. M. A. Suchard, S. E. Simpson, I. Zorych, P. Ryan, D. Madigan, Massive Parallelization of Serial Inference Algorithms for a Complex Generalized Linear Model. *ACM Trans. Model. Comput. Simul.* **23**, 1-17 (2013).
34. E. A. Voss *et al.*, Accuracy of an Automated Knowledge Base for Identifying Drug Adverse Reactions. *Journal of biomedical informatics*, (2016).
35. P. Avillach *et al.*, Design and validation of an automated method to detect known adverse drug reactions in MEDLINE: a contribution from the EU-ADR project. *Journal of the American Medical Informatics Association : JAMIA* **20**, 446-452 (2013).
36. H. Kilicoglu, G. Rosemblat, M. Fiszman, T. C. Rindflesch, Constructing a semantic predication gold standard from the biomedical literature. *BMC bioinformatics* **12**, 486 (2011).
37. U. F. a. D. Administration. vol. 2016.
38. J. Duke, J. Friedlin, X. Li, Consistency in the safety labeling of bioequivalent medications. *Pharmacoepidemiology and drug safety* **22**, 294-301 (2013).
39. A. F. Wisniewski *et al.*, Good Signal Detection Practices: Evidence from IMI PROTECT. *Drug safety* **39**, 469-490 (2016).
40. G. N. Noren, O. Caster, K. Juhlin, M. Lindquist, Zoo or savannah? Choice of training ground for evidence-based pharmacovigilance. *Drug safety* **37**, 655-659 (2014).

Supplementary materials

Document S1. Exposure definitions	2
Document S2. Outcome definitions	7
Acute liver injury.....	7
Acute myocardial infarction	8
Alopecia	9
Constipation.....	9
Decreased libido	10
Delirium	10
Diarrhea	11
Fracture	11
Gastrointestinal hemorrhage	12
Hyperprolactinemia	13
Hyponatremia	13
Hypotension.....	14
Hypothyroidism	15
Insomnia	15
Nausea.....	16
Open-angle glaucoma	16
Seizure	17
Stroke	18
Suicide and suicidal ideation	18
Tinnitus.....	19
Ventricular arrhythmia and sudden cardiac death.....	20
Vertigo.....	20
References	21
Document S3. Consistency with gold standard from randomized controlled trials.....	24
Figure S1. Estimates for all control hypotheses before and after calibration	26
Figure S2. Leave-one-out cross-validation of calibration	27
Figure S3. Comparison of results from RCTs and our observational study.....	28

Document S1. Exposure definitions

The target and comparator groups consisted of new users of the treatments listed in Table 1, which are identified using the codes specified in tables S1.1-S1.4. For both cohorts we restrict to people with a prior diagnosis of depression, and no prior history of bipolar disorder or schizophrenia.

Concept ID	Concept Name
4152280	Major depressive disorder
435783	Schizophrenia
436665	Bipolar disorder

Table S1.1. Concepts used to identify prior history of depression, schizophrenia, and bipolar disorders. All descendants of these concepts are also considered.

Concept ID	RxNorm ID	Concept Name
710062	704	Amitriptyline
750982	42347	Bupropion
797617	2556	Citalopram
717607	734064	Desvenlafaxine
738156	3638	Doxepin
715259	72625	duloxetine
715939	321988	Escitalopram
755695	4493	Fluoxetine
725131	15996	Mirtazapine
721724	7531	Nortriptyline
722031	32937	Paroxetine
739138	36437	Sertraline
703547	10737	Trazodone
743670	39786	venlafaxine
40234834	1086769	vilazodone

Table S1.2. The 15 included drugs and their concept identifiers. All descendants of these concepts are also considered.

Concept ID	Concept Name
4119335	Analytical psychology
4084202	Anti-criminal psychotherapy
4079608	Anti-suicide psychotherapy

4048385 Brief group psychotherapy
 4295027 Brief solution focused psychotherapy
 4299728 Client-centered psychotherapy
 4164790 Conjoint psychotherapy
 4208314 Couple psychotherapy
 4083706 Crisis intervention
 4083131 Daily life psychotherapy
 4121662 Developmental psychodynamic psychotherapy
 4226276 Eclectic psychotherapy
 4258834 Educational psychotherapy
 4148765 Encounter group therapy
 2007747 Exploratory verbal psychotherapy
 4137086 Expressed emotion family therapy
 4048387 Expressive psychotherapy
 4173581 Extended family therapy
 46286403 Family intervention for psychosis
 2213546 Family psychotherapy (conjoint psychotherapy) (with patient present)
 4028920 Family psychotherapy procedure
 46286330 Focal psychodynamic therapy
 4226275 Formal psychological therapy
 45765516 Functional family therapy
 4079939 Functional psychotherapy
 4079500 General psychotherapy
 4117915 Generic Jungian-based therapy
 4100341 Group analytical psychotherapy
 44808677 Group cognitive behavioural therapy
 4136352 Group marathon therapy
 4268909 Group primal therapy
 4296166 Group psychotherapy
 2213548 Group psychotherapy (other than of a multiple-family group)
 2617477 Group psychotherapy other than of a multiple-family group, in a partial hospitalization setting, approximately 45 to 50 minutes
 4196062 Group reassurance
 2213554 Individual psychophysiological therapy incorporating biofeedback training by any modality (face-to-face with the patient), with psychotherapy (eg, insight oriented, behavior modifying or supportive psychotherapy); 30 minutes
 2213555 Individual psychophysiological therapy incorporating biofeedback training by any modality (face-to-face with the patient), with psychotherapy (eg, insight oriented, behavior modifying or supportive psychotherapy); 45 minutes
 4088889 Individual psychotherapy
 2007730 Individual psychotherapy
 4103512 Interactive group medical psychotherapy

2617478 Interactive group psychotherapy, in a partial hospitalization setting, approximately 45 to 50 minutes

4221997 Interactive individual medical psychotherapy

40482841 Interpersonal psychotherapy

4119334 Jungian-based therapy

4118797 Long-term exploratory psychotherapy

4118798 Long-term psychodynamic psychotherapy

44792695 Marital psychotherapy

2213547 Multiple-family group psychotherapy

4118800 Narrative family psychotherapy

4242119 Occupational social therapy

2007749 Other individual psychotherapy

2007750 Other psychotherapy and counselling

45887728 Other Psychotherapy Procedures

45763911 Parent-infant psychotherapy

2007746 Play psychotherapy

4083133 Potential suicide care

4084195 Provocative therapy

2213544 Psychoanalysis

2007731 Psychoanalysis

4114491 Psychoanalytic and psychodynamic therapy

4202234 Psychodrama

2007763 Psychodrama

4199042 Psychodynamic psychotherapy

4128268 Psychodynamic-interpersonal psychotherapy

4118801 Psychotherapeutic approaches using specific settings

4327941 Psychotherapy

4083129 Psychotherapy - behavioral

4079938 Psychotherapy - cognitive

45889353 Psychotherapy for crisis

45888237 Psychotherapy for Crisis Services and Procedures

43527991 Psychotherapy for crisis; each additional 30 minutes (List separately in addition to code for primary service)

43527990 Psychotherapy for crisis; first 60 minutes

45887951 Psychotherapy Services and Procedures

2108571 Psychotherapy services provided (MDD, MDD ADOL)

43527986 Psychotherapy, 30 minutes with patient and/or family member

43527987 Psychotherapy, 30 minutes with patient and/or family member when performed with an evaluation and management service (List separately in addition to the code for primary procedure)

43527904 Psychotherapy, 45 minutes with patient and/or family member

43527988	Psychotherapy, 45 minutes with patient and/or family member when performed with an evaluation and management service (List separately in addition to the code for primary procedure)
43527905	Psychotherapy, 60 minutes with patient and/or family member
43527989	Psychotherapy, 60 minutes with patient and/or family member when performed with an evaluation and management service (List separately in addition to the code for primary procedure)
4148398	Psychotherapy/sociotherapy
4083130	Rehabilitation for disabling psychiatric problem
44791916	Relationship psychosexual therapy
4265313	Relationship psychotherapy
4084201	Samaritans advisory service
4233181	Sensate focus technique
4272803	Sexual psychotherapy
4035812	Sexual psychotherapy, female therapist - female patient
4012488	Sexual psychotherapy, female therapist - male patient
4132436	Sexual psychotherapy, group
4143316	Sexual psychotherapy, group, all female
4219683	Sexual psychotherapy, group, all male
4151904	Sexual psychotherapy, group, male and female
4278094	Sexual psychotherapy, male therapist - female patient
4249602	Sexual psychotherapy, male therapist - male patient
4234476	Sexual surrogate therapy
4179241	Short-term psychodynamic therapy
4234402	Social psychotherapy
4128406	Specific task orientated psychotherapy
4080044	Stimulative psychotherapy
4262582	Structural family psychotherapy
4263758	Structural psychotherapy
4126653	Supportive expressive psychodynamic psychotherapy
4311943	Supportive verbal psychotherapy
2007748	Supportive verbal psychotherapy
4225728	Suppressive psychotherapy
4080048	Therapeutic psychology
44808259	Therapeutic role play

Table S1.3. Concepts used to identify psychotherapy.

Concept ID	Concept Name
4111663	Bilateral electroconvulsive therapy
4030840	Electroconvulsive therapy
2108578	Electroconvulsive therapy (ECT) provided (MDD)
2213552	Electroconvulsive therapy (includes necessary monitoring)

4020981	Electronarcosis
4210144	First treatment in a course of electroconvulsive therapy
4336318	Multiple electroconvulsive therapy
4332436	Multiple monitored electroconvulsive therapy
2007728	Other electroshock therapy
44508134	Other specified electroconvulsive therapy
2108579	Patient referral for electroconvulsive therapy (ECT) documented (MDD)
2007727	Subconvulsive electroshock therapy
4004830	Subconvulsive electroshock therapy
4210145	Subsequent treatment in a course of electroconvulsive therapy

Table S1.4. Concepts used to identify electroconvulsive therapy.

Document S2. Outcome definitions

This section describes the algorithms we use to identify occurrences of the 22 outcomes of interest. The algorithms are framed in the context of the OMOP Common Data Model¹¹ (CDM) version 5. The CDM uses a standardized terminology for encoding all information. For more information on the CDM and the standard vocabulary see <http://ohdsi.org>. The computer-executable version of these algorithms is part of the study R package:

<https://github.com/OHDSI/StudyProtocols/tree/master/LargeScalePopEst>

Acute liver injury

Note: This algorithm uses the set of codes identified by Udo et al. ¹²

Initial Event Cohort

People having any of the following:

- a condition occurrence of acute liver injury¹
 - for the first time in the person's history
 - visit occurrence is any of: Emergency Room Visit, Inpatient Visit

with continuous observation of at least 0 days prior and 0 days after event index date, and limit initial events to: **earliest event per person.**

For people matching the Primary Events, include:

Having all of the following criteria:

- exactly 0 occurrences of a condition occurrence of acute liver injury exclusion concepts²
starting between 365 days Before and 60 days After event index date

Limit cohort of initial events to: **earliest event per person.**

Limit qualifying cohort to: **earliest event per person.**

No end date strategy selected. By default, the cohort end date will be the end of the observation period that contains the index event.

Appendix 1: Concept Set Definitions

1. acute liver injury

Concept Id	Concept Name	Domain	Vocabulary	Excluded	Descendants	Mapped
200763	Chronic hepatitis	Condition	SNOMED	YES	YES	NO
377604	Hepatic coma	Condition	SNOMED	NO	YES	NO

Concept Id	Concept Name	Domain	Vocabulary	Excluded	Descendants	Mapped
196029	Hepatic coma due to viral hepatitis	Condition	SNOMED	YES	YES	NO
4337543	Hepatic necrosis	Condition	SNOMED	NO	YES	NO
194087	Hepatitis due to infection	Condition	SNOMED	YES	YES	NO
196455	Hepatorenal syndrome	Condition	SNOMED	NO	YES	NO
194990	Inflammatory disease of liver	Condition	SNOMED	NO	YES	NO
4291005	Viral hepatitis	Condition	SNOMED	YES	YES	NO

2. acute liver injury exclusion concepts

Concept Id	Concept Name	Domain	Vocabulary	Excluded	Descendants	Mapped
192956	Cholecystitis	Condition	SNOMED	NO	YES	NO
200763	Chronic hepatitis	Condition	SNOMED	NO	YES	NO
4212540	Chronic liver disease	Condition	SNOMED	NO	YES	NO
197917	Disorder of biliary tract	Condition	SNOMED	NO	YES	NO
192353	Disorder of gallbladder	Condition	SNOMED	NO	YES	NO
192963	Disorder of pancreas	Condition	SNOMED	NO	YES	NO
196456	Gallstone	Condition	SNOMED	NO	YES	NO
4130518	Neoplasm of liver	Condition	SNOMED	NO	YES	NO
4291005	Viral hepatitis	Condition	SNOMED	NO	YES	NO

Acute myocardial infarction

Initial Event Cohort

People having any of the following:

- a condition occurrence of Acute MI¹
 - for the first time in the person's history
 - condition type is any of: Inpatient detail - primary, Inpatient header - primary, Primary Condition, Inpatient detail - 1st position, Inpatient header - 1st position
 - visit occurrence is any of: Emergency Room Visit, Inpatient Visit

with continuous observation of at least 0 days prior and 0 days after event index date, and limit initial events to: **earliest event per person.**

Limit qualifying cohort to: **earliest event per person.**

No end date strategy selected. By default, the cohort end date will be the end of the observation period that contains the index event.

Appendix 1: Concept Set Definitions

1. Acute MI

Concept Id	Concept Name	Domain	Vocabulary	Excluded	Descendants	Mapped
4329847	Myocardial infarction	Condition	SNOMED	NO	YES	NO
314666	Old myocardial infarction	Condition	SNOMED	YES	YES	NO

Alopecia

Initial Event Cohort

People having any of the following:

- a condition occurrence of Alopecia¹
 - for the first time in the person's history

with continuous observation of at least 0 days prior and 0 days after event index date, and limit initial events to: **earliest event per person.**

Limit qualifying cohort to: **earliest event per person.**

No end date strategy selected. By default, the cohort end date will be the end of the observation period that contains the index event.

Appendix 1: Concept Set Definitions

1. Alopecia

Concept Id	Concept Name	Domain	Vocabulary	Excluded	Descendants	Mapped
133280	Alopecia	Condition	SNOMED	NO	YES	NO
133959	Syphilitic alopecia	Condition	SNOMED	YES	YES	NO

Constipation

Note: This algorithm requires the occurrence of 2 or more diagnoses, as recommended by Mody et al.¹³

Initial Event Cohort

People having any of the following:

- a condition occurrence of Constipation¹
 - for the first time in the person's history

with continuous observation of at least 0 days prior and 0 days after event index date, and limit initial events to: **earliest event per person.**

Limit qualifying cohort to: **earliest event per person.**

No end date strategy selected. By default, the cohort end date will be the end of the observation period that contains the index event.

Appendix 1: Concept Set Definitions

1. Constipation

Concept Id	Concept Name	Domain	Vocabulary	Excluded	Descendants	Mapped
75860	Constipation	Condition	SNOMED	NO	YES	NO

Decreased libido

Initial Event Cohort

People having any of the following:

- a condition occurrence of Decreased libido¹
 - for the first time in the person's history

with continuous observation of at least 0 days prior and 0 days after event index date, and limit initial events to: **earliest event per person.**

Limit qualifying cohort to: **earliest event per person.**

No end date strategy selected. By default, the cohort end date will be the end of the observation period that contains the index event.

Appendix 1: Concept Set Definitions

1. Decreased libido

Concept Id	Concept Name	Domain	Vocabulary	Excluded	Descendants	Mapped
436246	Reduced libido	Condition	SNOMED	NO	YES	NO

Delirium

Note: This algorithm relies on diagnosis codes associated with hospitalization. This approach may lead to underreporting, as described by McCoy et al. ¹⁴

Initial Event Cohort

People having any of the following:

- a condition occurrence of Delirium¹
 - for the first time in the person's history
 - visit occurrence is any of: Emergency Room Visit, Inpatient Visit

with continuous observation of at least 0 days prior and 0 days after event index date, and limit initial events to: **earliest event per person.**

Limit qualifying cohort to: **earliest event per person.**

No end date strategy selected. By default, the cohort end date will be the end of the observation period that contains the index event.

Appendix 1: Concept Set Definitions

1. Delirium

Concept Id	Concept Name	Domain	Vocabulary	Excluded	Descendants	Mapped
377830	Alcohol withdrawal delirium	Condition	SNOMED	YES	YES	NO
373995	Delirium	Condition	SNOMED	NO	YES	NO

Diarrhea

Note: This algorithm follows Broder et al. ¹⁵

Initial Event Cohort

People having any of the following:

- a condition occurrence of Diarrhea¹
 - for the first time in the person's history

with continuous observation of at least 0 days prior and 0 days after event index date, and limit initial events to: **earliest event per person.**

Limit qualifying cohort to: **earliest event per person.**

No end date strategy selected. By default, the cohort end date will be the end of the observation period that contains the index event.

Appendix 1: Concept Set Definitions

1. Diarrhea

Concept Id	Concept Name	Domain	Vocabulary	Excluded	Descendants	Mapped
196523	Diarrhea	Condition	SNOMED	NO	YES	NO
80141	Functional diarrhea	Condition	SNOMED	NO	YES	NO

Fracture

Note: This algorithm follows Lanteigne et al. ¹⁶

Initial Event Cohort

People having any of the following:

- a condition occurrence of Fracture¹
 - for the first time in the person's history

with continuous observation of at least 0 days prior and 0 days after event index date, and limit initial events to: **earliest event per person.**

Limit qualifying cohort to: **earliest event per person.**

No end date strategy selected. By default, the cohort end date will be the end of the observation period that contains the index event.

Appendix 1: Concept Set Definitions

1. Fracture

Concept Id	Concept Name	Domain	Vocabulary	Excluded	Descendants	Mapped
435093	Closed fracture of femur	Condition	SNOMED	NO	YES	NO
441974	Closed fracture of forearm	Condition	SNOMED	NO	YES	NO
4230399	Closed fracture of hip	Condition	SNOMED	NO	YES	NO
441422	Closed fracture of humerus	Condition	SNOMED	NO	YES	NO
439166	Closed fracture of radius	Condition	SNOMED	NO	YES	NO
4278672	Fracture of forearm	Condition	SNOMED	NO	YES	NO
442619	Fracture of humerus	Condition	SNOMED	NO	YES	NO
433856	Fracture of neck of femur	Condition	SNOMED	NO	YES	NO
4131595	Fracture of radius	Condition	SNOMED	NO	YES	NO
73571	Pathological fracture	Condition	SNOMED	NO	YES	NO

Gastrointestinal hemorrhage

Initial Event Cohort

People having any of the following:

- a condition occurrence of Gastrointestinal hemorrhage¹
 - for the first time in the person's history
 - condition type is any of: Inpatient detail - primary, Inpatient header - primary, Primary Condition, Inpatient detail - 1st position, Inpatient header - 1st position
 - visit occurrence is any of: Emergency Room Visit, Inpatient Visit

with continuous observation of at least 0 days prior and 0 days after event index date, and limit initial events to: **earliest event per person.**

Limit qualifying cohort to: **earliest event per person.**

No end date strategy selected. By default, the cohort end date will be the end of the observation period that contains the index event.

Appendix 1: Concept Set Definitions

1. Gastrointestinal hemorrhage

Concept Id	Concept Name	Domain	Vocabulary	Excluded	Descendants	Mapped
4280942	Acute gastrojejunal ulcer with perforation	Condition	SNOMED	NO	YES	NO
28779	Bleeding esophageal varices	Condition	SNOMED	NO	YES	NO
198798	Dieulafoy's vascular malformation	Condition	SNOMED	NO	YES	NO
4112183	Esophageal varices with bleeding, associated with another disorder	Condition	SNOMED	NO	YES	NO

Concept Id	Concept Name	Domain	Vocabulary	Excluded	Descendants	Mapped
194382	External hemorrhoids	Condition	SNOMED	NO	NO	NO
192671	Gastrointestinal hemorrhage	Condition	SNOMED	NO	YES	NO
196436	Internal hemorrhoids	Condition	SNOMED	NO	NO	NO
4338225	Peptic ulcer with perforation	Condition	SNOMED	NO	YES	NO
194158	Perinatal gastrointestinal hemorrhage	Condition	SNOMED	YES	YES	NO

Hyperprolactinemia

Initial Event Cohort

People having any of the following:

- a condition occurrence of Hyperprolactinemia¹
 - for the first time in the person's history

with continuous observation of at least 0 days prior and 0 days after event index date, and limit initial events to: **earliest event per person.**

Limit qualifying cohort to: **earliest event per person.**

No end date strategy selected. By default, the cohort end date will be the end of the observation period that contains the index event.

Appendix 1: Concept Set Definitions

1. Hyperprolactinemia

Concept Id	Concept Name	Domain	Vocabulary	Excluded	Descendants	Mapped
4030186	Hyperprolactinemia	Condition	SNOMED	NO	YES	NO

Hyponatremia

Note: The algorithm here relies on the recording of diagnoses codes, and might not have high sensitivity as remarked by Shea et al.

Initial Event Cohort

People having any of the following:

- a condition occurrence of Hyponatremia¹
 - for the first time in the person's history
- a measurement of Serum sodium²
 - for the first time in the person's history
 - with value as number < 136
 - unit is any of: millimole per liter

with continuous observation of at least 0 days prior and 0 days after event index date, and limit initial events to: **earliest event per person.**

Limit qualifying cohort to: **earliest event per person.**

No end date strategy selected. By default, the cohort end date will be the end of the observation period that contains the index event.

Appendix 1: Concept Set Definitions

1. Hyponatremia

Concept Id	Concept Name	Domain	Vocabulary	Excluded	Descendants	Mapped
435515	Hypo-osmolality and or hyponatremia	Condition	SNOMED	NO	YES	NO

2. Serum sodium

Concept Id	Concept Name	Domain	Vocabulary	Excluded	Descendants	Mapped
3032987	Sodium [Moles/volume] corrected for glucose in Serum or Plasma	Measurement	LOINC	NO	YES	NO
46235784	Sodium [Moles/volume] in Serum, Plasma or Blood	Measurement	LOINC	NO	YES	NO
3019550	Sodium serum/plasma	Measurement	LOINC	NO	YES	NO

[Hypotension](#)

Note: This algorithm follows Wernli et al. ¹⁷

Initial Event Cohort

People having any of the following:

- a condition occurrence of Hypotension¹
 - for the first time in the person's history

with continuous observation of at least 0 days prior and 0 days after event index date, and limit initial events to: **earliest event per person.**

Limit qualifying cohort to: **earliest event per person.**

No end date strategy selected. By default, the cohort end date will be the end of the observation period that contains the index event.

Appendix 1: Concept Set Definitions

1. Hypotension

Concept Id	Concept Name	Domain	Vocabulary	Excluded	Descendants	Mapped
4120275	Drug-induced hypotension	Condition	SNOMED	NO	YES	NO
317002	Low blood pressure	Condition	SNOMED	NO	YES	NO

Concept Id	Concept Name	Domain	Vocabulary	Excluded	Descendants	Mapped
314432	Maternal hypotension syndrome	Condition	SNOMED	YES	YES	NO
319041	Orthostatic hypotension	Condition	SNOMED	NO	YES	NO

Hypothyroidism

Note: This algorithm requires the occurrences of 2 more diagnose codes, as recommended by Lu et al. ¹⁸

Initial Event Cohort

People having any of the following:

- a condition occurrence of Hypothyroidism¹

with continuous observation of at least 0 days prior and 0 days after event index date, and limit initial events to: **all events per person.**

For people matching the Primary Events, include:

Having all of the following criteria:

- at least 2 occurrences of a condition occurrence of Hypothyroidism¹

starting between 0 days Before and 90 days After event index date

Limit cohort of initial events to: **earliest event per person.**

Limit qualifying cohort to: **earliest event per person.**

No end date strategy selected. By default, the cohort end date will be the end of the observation period that contains the index event.

Appendix 1: Concept Set Definitions

1. Hypothyroidism

Concept Id	Concept Name	Domain	Vocabulary	Excluded	Descendants	Mapped
140673	Hypothyroidism	Condition	SNOMED	NO	YES	NO

Insomnia

Initial Event Cohort

People having any of the following:

- a condition occurrence of Insomnia¹
 - for the first time in the person's history

with continuous observation of at least 0 days prior and 0 days after event index date, and limit initial events to: **earliest event per person.**

Limit qualifying cohort to: **earliest event per person.**

No end date strategy selected. By default, the cohort end date will be the end of the observation period that contains the index event.

Appendix 1: Concept Set Definitions

1. Insomnia

Concept Id	Concept Name	Domain	Vocabulary	Excluded	Descendants	Mapped
439708	Disorders of initiating and maintaining sleep	Condition	SNOMED	NO	YES	NO
436962	Insomnia	Condition	SNOMED	NO	YES	NO
4305303	Sleep deprivation	Condition	SNOMED	NO	YES	NO

[Nausea](#)

Initial Event Cohort

People having any of the following:

- a condition occurrence of Nausea¹
 - for the first time in the person's history

with continuous observation of at least 0 days prior and 0 days after event index date, and limit initial events to: **earliest event per person.**

Limit qualifying cohort to: **earliest event per person.**

No end date strategy selected. By default, the cohort end date will be the end of the observation period that contains the index event.

Appendix 1: Concept Set Definitions

1. Nausea

Concept Id	Concept Name	Domain	Vocabulary	Excluded	Descendants	Mapped
30284	Motion sickness	Condition	SNOMED	YES	YES	NO
31967	Nausea	Condition	SNOMED	NO	YES	NO

[Open-angle glaucoma](#)

Note: This algorithm follows Stein et al. ¹⁹

Initial Event Cohort

People having any of the following:

- a condition occurrence of Open-angle glaucoma¹
 - for the first time in the person's history

with continuous observation of at least 365 days prior and 0 days after event index date, and limit initial events to: **earliest event per person.**

For people matching the Primary Events, include:

Having all of the following criteria:

- at least 1 occurrences of a condition occurrence of Open-angle glaucoma¹
 - provider specialty is any of: Ophthalmology, Optometry, Optician

starting between 1 days After and 365 days After event index date

Limit cohort of initial events to: **earliest event per person.**

Limit qualifying cohort to: **all events per person.**

No end date strategy selected. By default, the cohort end date will be the end of the observation period that contains the index event.

Appendix 1: Concept Set Definitions

1. Open-angle glaucoma

Concept Id	Concept Name	Domain	Vocabulary	Excluded	Descendants	Mapped
432908	Glaucomatocyclitic crisis	Condition	SNOMED	YES	YES	NO
441561	Low tension glaucoma	Condition	SNOMED	NO	YES	NO
4216823	Open angle with borderline findings	Condition	SNOMED	YES	YES	NO
441284	Open-angle glaucoma	Condition	SNOMED	NO	YES	NO
4072218	Secondary open-angle glaucoma	Condition	SNOMED	YES	YES	NO

Seizure

Note: This algorithm requires either inpatient or emergency room visits as recommended by Wu et al.²⁰

Initial Event Cohort

People having any of the following:

- a condition occurrence of Seizure and seizure disorder¹
 - for the first time in the person's history
 - visit occurrence is any of: Emergency Room Visit, Inpatient Visit

with continuous observation of at least 0 days prior and 0 days after event index date, and limit initial events to: **earliest event per person.**

Limit qualifying cohort to: **earliest event per person.**

No end date strategy selected. By default, the cohort end date will be the end of the observation period that contains the index event.

Appendix 1: Concept Set Definitions

1. Seizure and seizure disorder

Concept Id	Concept Name	Domain	Vocabulary	Excluded	Descendants	Mapped
380533	Convulsions in the newborn	Condition	SNOMED	YES	YES	NO
45757050	Epilepsy in mother complicating pregnancy	Condition	SNOMED	YES	YES	NO
377091	Seizure	Condition	SNOMED	NO	YES	NO
4029498	Seizure disorder	Condition	SNOMED	NO	YES	NO

[Stroke](#)

Initial Event Cohort

People having any of the following:

- a condition occurrence of Ischemic stroke¹
 - for the first time in the person's history
 - visit occurrence is any of: Inpatient Visit

with continuous observation of at least 0 days prior and 0 days after event index date, and limit initial events to: **earliest event per person.**

Limit qualifying cohort to: **earliest event per person.**

No end date strategy selected. By default, the cohort end date will be the end of the observation period that contains the index event.

Appendix 1: Concept Set Definitions

1. Ischemic stroke

Concept Id	Concept Name	Domain	Vocabulary	Excluded	Descendants	Mapped
374060	Acute ill-defined cerebrovascular disease	Condition	SNOMED	NO	YES	NO
4108356	Cerebral infarction due to embolism of cerebral arteries	Condition	SNOMED	NO	YES	NO
4110192	Cerebral infarction due to thrombosis of cerebral arteries	Condition	SNOMED	NO	YES	NO
4043731	Infarction - precerebral	Condition	SNOMED	NO	YES	NO

[Suicide and suicidal ideation](#)

Note: This algorithm is based on the review by Callagan et al. ²¹

Initial Event Cohort

People having any of the following:

- a condition occurrence of Suicide and suicidal ideation¹
 - for the first time in the person's history
- an observation of Suicide and suicidal ideation¹
 - for the first time in the person's history

with continuous observation of at least 0 days prior and 0 days after event index date, and limit initial events to: **earliest event per person.**

Limit qualifying cohort to: **earliest event per person.**

No end date strategy selected. By default, the cohort end date will be the end of the observation period that contains the index event.

Appendix 1: Concept Set Definitions

1. Suicide and suicidal ideation

Concept Id	Concept Name	Domain	Vocabulary	Excluded	Descendants	Mapped
439235	Self inflicted injury	Condition	SNOMED	NO	YES	NO
4181216	Self-administered poisoning	Condition	SNOMED	NO	YES	NO
444362	Suicidal deliberate poisoning	Condition	SNOMED	NO	YES	NO
4273391	Suicidal thoughts	Condition	SNOMED	NO	YES	NO
440925	Suicide	Observation	SNOMED	NO	YES	NO

Tinnitus

Note: This algorithm follows Lee et al. ²²

Initial Event Cohort

People having any of the following:

- a condition occurrence of Tinnitus¹
 - for the first time in the person's history

with continuous observation of at least 0 days prior and 0 days after event index date, and limit initial events to: **earliest event per person.**

Limit qualifying cohort to: **earliest event per person.**

No end date strategy selected. By default, the cohort end date will be the end of the observation period that contains the index event.

Appendix 1: Concept Set Definitions

1. Tinnitus

Concept Id	Concept Name	Domain	Vocabulary	Excluded	Descendants	Mapped
377575	Tinnitus	Condition	SNOMED	NO	YES	NO

Ventricular arrhythmia and sudden cardiac death

Note: This algorithm follows the definition used by Leonard et al. ²³

Initial Event Cohort

People having any of the following:

- a condition occurrence of Ventricular arrhythmia and sudden cardiac death¹
 - for the first time in the person's history
 - condition type is any of: Inpatient detail - primary, Inpatient header - primary, Primary Condition, Carrier claim detail - 1st position, Carrier claim header - 1st position, Inpatient detail - 1st position, Inpatient header - 1st position, Outpatient detail - 1st position, Outpatient header - 1st position
 - visit occurrence is any of: Emergency Room Visit, Inpatient Visit

with continuous observation of at least 0 days prior and 0 days after event index date, and limit initial events to: **earliest event per person.**

Limit qualifying cohort to: **earliest event per person.**

No end date strategy selected. By default, the cohort end date will be the end of the observation period that contains the index event.

Appendix 1: Concept Set Definitions

1. Ventricular arrhythmia and sudden cardiac death

Concept Id	Concept Name	Domain	Vocabulary	Excluded	Descendants	Mapped
321042	Cardiac arrest	Condition	SNOMED	NO	YES	NO
442289	Death in less than 24 hours from onset of symptoms	Observation	SNOMED	NO	YES	NO
441139	Instantaneous death	Observation	SNOMED	NO	YES	NO
4132309	Sudden death	Observation	SNOMED	NO	YES	NO
4185572	Ventricular arrhythmia	Condition	SNOMED	NO	YES	NO
437894	Ventricular fibrillation	Condition	SNOMED	NO	YES	NO
4103295	Ventricular tachycardia	Condition	SNOMED	NO	YES	NO

Vertigo

Initial Event Cohort

People having any of the following:

- a condition occurrence of Vertigo¹
 - for the first time in the person's history

with continuous observation of at least 0 days prior and 0 days after event index date, and limit initial events to: **earliest event per person.**

Limit qualifying cohort to: **earliest event per person.**

No end date strategy selected. By default, the cohort end date will be the end of the observation period that contains the index event.

Appendix 1: Concept Set Definitions

1. Vertigo

Concept Id	Concept Name	Domain	Vocabulary	Excluded	Descendants	Mapped
78162	Peripheral vertigo	Condition	SNOMED	NO	YES	NO
439383	Vertigo	Condition	SNOMED	NO	YES	NO
381035	Vertigo of central origin	Condition	SNOMED	NO	YES	NO

References

1. Voss EA, Boyce RD, Ryan PB, et al. Accuracy of an Automated Knowledge Base for Identifying Drug Adverse Reactions. *Journal of biomedical informatics* 2016 doi: 10.1016/j.jbi.2016.12.005 [published Online First: 2016/12/21]
2. Avillach P, Dufour JC, Diallo G, et al. Design and validation of an automated method to detect known adverse drug reactions in MEDLINE: a contribution from the EU-ADR project. *Journal of the American Medical Informatics Association : JAMIA* 2013;20(3):446-52. doi: 10.1136/amiainl-2012-001083 [published Online First: 2012/12/01]
3. Kilicoglu H, Roseblat G, Fiszman M, et al. Constructing a semantic predication gold standard from the biomedical literature. *BMC bioinformatics* 2011;12:486. doi: 10.1186/1471-2105-12-486 [published Online First: 2011/12/22]
4. Administration UFaD. FDA Adverse Event Reporting System (FAERS) [Available from: <http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/2016>.
5. Duke J, Friedlin J, Li X. Consistency in the safety labeling of bioequivalent medications. *Pharmacoepidemiology and drug safety* 2013;22(3):294-301. doi: 10.1002/pds.3351 [published Online First: 2012/10/09]
6. Wisniewski AF, Bate A, Bousquet C, et al. Good Signal Detection Practices: Evidence from IMI PROTECT. *Drug safety* 2016;39(6):469-90. doi: 10.1007/s40264-016-0405-1 [published Online First: 2016/03/10]
7. Noren GN, Caster O, Juhlin K, et al. Zoo or savannah? Choice of training ground for evidence-based pharmacovigilance. *Drug safety* 2014;37(9):655-9. doi: 10.1007/s40264-014-0198-z [published Online First: 2014/07/10]
8. Schuemie MJ, Hripcsak G, Ryan PB, et al. Empirical confidence interval calibration for population-level effect estimation studies in observational healthcare data. *Proceedings of the National Academy of Science* 2017; Accepted for publication

9. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. *Biometrika* 1983;70(1):41-55. doi: 10.1093/biomet/70.1.41
10. Suchard MA, Simpson SE, Zorych I, et al. Massive Parallelization of Serial Inference Algorithms for a Complex Generalized Linear Model. *ACM Trans Model Comput Simul* 2013;23(1):1-17. doi: 10.1145/2414416.2414791
11. Overhage JM, Ryan PB, Reich CG, et al. Validation of a common data model for active safety surveillance research. *Journal of the American Medical Informatics Association : JAMIA* 2012;19(1):54-60. doi: 10.1136/amiajnl-2011-000376 [published Online First: 2011/11/01]
12. Udo R, Maitland-van der Zee AH, Egberts TC, et al. Validity of diagnostic codes and laboratory measurements to identify patients with idiopathic acute liver injury in a hospital database. *Pharmacoepidemiology and drug safety* 2016;25 Suppl 1:21-8. doi: 10.1002/pds.3824 [published Online First: 2015/07/07]
13. Mody R, Guerin A, Fok B, et al. Prevalence and risk of developing comorbid conditions in patients with chronic constipation. *Current medical research and opinion* 2014;30(12):2505-13. doi: 10.1185/03007995.2014.964854 [published Online First: 2014/09/13]
14. McCoy TH, Jr., Snapper L, Stern TA, et al. Underreporting of Delirium in Statewide Claims Data: Implications for Clinical Care and Predictive Modeling. *Psychosomatics* 2016;57(5):480-8. doi: 10.1016/j.psych.2016.06.001 [published Online First: 2016/08/03]
15. Broder MS, Chang E, Romanus D, et al. Healthcare and economic impact of diarrhea in patients with carcinoid syndrome. *World journal of gastroenterology* 2016;22(6):2118-25. doi: 10.3748/wjg.v22.i6.2118 [published Online First: 2016/02/16]
16. Lanteigne A, Sheu YH, Sturmer T, et al. Serotonin-norepinephrine reuptake inhibitor and selective serotonin reuptake inhibitor use and risk of fractures: a new-user cohort study among US adults aged 50 years and older. *CNS drugs* 2015;29(3):245-52. doi: 10.1007/s40263-015-0231-5 [published Online First: 2015/02/25]
17. Wernli KJ, Brenner AT, Rutter CM, et al. Risks Associated With Anesthesia Services During Colonoscopy. *Gastroenterology* 2016;150(4):888-94; quiz e18. doi: 10.1053/j.gastro.2015.12.018 [published Online First: 2015/12/29]
18. Lu MC, Chang SC, Huang KY, et al. Higher Risk of Thyroid Disorders in Young Patients with Type 1 Diabetes: A 12-Year Nationwide, Population-Based, Retrospective Cohort Study. *PLoS one* 2016;11(3):e0152168. doi: 10.1371/journal.pone.0152168 [published Online First: 2016/03/24]
19. Stein JD, Blachley TS, Musch DC. Identification of persons with incident ocular diseases using health care claims databases. *American journal of ophthalmology* 2013;156(6):1169-75 e3. doi: 10.1016/j.ajo.2013.06.035 [published Online First: 2013/08/27]
20. Wu CS, Wang SC, Yeh IJ, et al. Comparative risk of seizure with use of first- and second-generation antipsychotics in patients with schizophrenia and mood disorders. *The Journal of clinical psychiatry* 2016;77(5):e573-9. doi: 10.4088/JCP.15m09898 [published Online First: 2016/06/02]
21. Callahan ST, Fuchs DC, Shelton RC, et al. Identifying suicidal behavior among adolescents using administrative claims data. *Pharmacoepidemiology and drug safety* 2013;22(7):769-75. doi: 10.1002/pds.3421 [published Online First: 2013/02/16]

22. Lee CF, Lin MC, Lin HT, et al. Increased risk of tinnitus in patients with temporomandibular disorder: a retrospective population-based cohort study. *European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery* 2016;273(1):203-8. doi: 10.1007/s00405-015-3491-2 [published Online First: 2015/01/13]
23. Leonard CE, Bilker WB, Newcomb C, et al. Antidepressants and the risk of sudden cardiac death and ventricular arrhythmia. *Pharmacoepidemiology and drug safety* 2011;20(9):903-13. doi: 10.1002/pds.2181 [published Online First: 2011/07/29]

Document S3. Consistency with gold standard from randomized controlled trials

Sertraline increases risk of diarrhea relative to comparators: Across all four databases, we consistently observe sertraline having an increased risk of diarrhea relative to most comparator treatments, with the magnitude of effect estimates ranging from 20% to 100% increased risk. In MDCR, we produce estimates for 11 comparisons with sertraline, 10 of which yield calibrated 95% confidence intervals greater than 1: nortriptyline HR=2.10 (95% CI: 1.51-2.91); psychotherapy HR=1.96 (95% CI: 1.22-3.41); fluoxetine HR=1.71 (95% CI: 1.34-2.20); sertraline HR=1.68 (95% CI: 1.44-1.97); venlafaxine HR=1.58 (95% CI: 1.35-1.86); amitriptyline HR=1.56 (95% CI: 1.10-2.37); duloxetine HR=1.33 (95% CI: 1.09-1.68); trazodone HR=1.33 (95% CI: 1.12-1.59); citalopram HR=1.31 (95% CI: 1.15-1.49); escitalopram HR=1.22 (95% CI: 1.07-1.40); and mirtazapine HR=1.16 (95% CI: 0.98-1.38). All comparisons in MDCR except psychotherapy pass all empirical diagnostics, with sufficient sample near clinical equipoise, adequate covariate balance, and empirical calibration demonstrating nominal operating characteristics. For the comparison with psychotherapy, inadequate covariate balance remains after propensity score adjustment, suggesting the potential for residual bias.

Venlafaxine increases risk of nausea relative to SSRIs: Amongst the two privately-insured populations (CCAIE and Optum), we find consistent evidence of a small increased risk of nausea between new users of venlafaxine and the most prevalent SSRIs – sertraline, escitalopram, and citalopram. When comparing the risk of nausea between new users of venlafaxine and sertraline in the CCAIE database, the estimated calibrated HR is 1.07 (95% CI: 0.91-1.26), and Optum returns a similar effect estimate [HR=1.10 (95% CI: 1.00-1.22)]. When comparing the risk of nausea between new users of venlafaxine and escitalopram, the estimated calibrated HR in CCAIE is HR=1.12 (95% CI: 1.01-1.25) and in Optum is HR=1.12 (95% CI: 0.97-1.30). When comparing the risk of nausea between new users of venlafaxine and citalopram, the estimated calibrated HR in CCAIE is HR=1.08 (95% CI: 1.00-1.18) and in Optum is HR=1.05 (95% CI: 0.95-1.18). Across all databases, comparisons between venlafaxine and each SSRI demonstrate sufficient clinical equipoise, adequate covariate balance, and empirical calibration restores nominal operating characteristics. Compared with the clinical trial results, the observational

studies have a lower incidence of nausea, and are directionally consistent but had a small magnitude of effect estimate.

No difference in nausea between duloxetine and paroxetine or fluoxetine: All four databases produce estimates comparing the duloxetine with fluoxetine, all of which consistently suggested no association. In CCAE, when comparing the risk of nausea between new users of duloxetine and fluoxetine, the estimated calibrated HR is 0.93 (95% CI: 0.79-1.12). Relative to paroxetine, the estimated calibrated HR is 1.01 (95% CI: 0.85-1.19). These observational studies allow the use of large samples to bound the magnitude of any potential effect to increase confidence in any conclusion around non-inferiority.

Paroxetine higher rate of sexual dysfunction than fluoxetine and sertraline: Among clinical trials of SSRIs, paroxetine is observed to have non-significant higher rates of sexual dysfunction than fluoxetine and sertraline. Across our observational databases, paroxetine is the least commonly used SSRI. In our largest dataset (CCAЕ), there are <8000 new users used in each analysis. While the review compared treatments for the broadly defined 'sexual dysfunction' outcome, we estimate effects for a more narrowly defined diagnosis of 'decreased libido', and the incidence of events is lower in observational data than reported in the trials. When comparing the risk of decreased libido between new users of paroxetine and fluoxetine, the estimated calibrated HR is 1.40 (95% CI: 0.84-2.34), and in comparison with sertraline, the estimated calibrated HR is 1.39 (95% CI: 0.86-2.26).

Figure S1. Estimates for all control hypotheses before and after calibration




Figure S1. Hazard ratios and corresponding standard errors estimated through our systematic evidence generation process to four observational databases for our negative and positive controls before (top) and after (bottom) calibration. The estimates are stratified by the true hazard ratio. Note that due to limitations in sample size not all negative controls could be used to synthesize positive controls, and a small fraction of estimates could therefore not be calibrated.

Figure S2. Leave-one-out cross-validation of calibration

To validate our confidence interval calibration procedure we use a leave-one-out cross-validation. For each negative control and the positive controls derived from that negative control, we fit systematic error models using all other controls, and compute confidence intervals for the left-out controls with a wide range of widths. We subsequently check how often the confidence intervals contained the true hazard ratio. In each fold of the cross-validation, error models are computed separately for each combination of target, comparator, and database. Figure S3 shows the coverage as a function of width of the confidence interval, stratified by the true hazard ratio.




Figure S2. Coverage of confidence intervals, per width of the confidence interval, and stratified by true hazard ratio.

Figure S3. Comparison of results from RCTs and our observational study




Figure S3. Effect size estimates on Sertraline compared to various other drugs for the outcome of diarrhea. Estimates from RCTs are those reported in Cipriani et al (2010). Observational estimates are the hazard ratios and 95% calibrated confidence intervals generated in our study.